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ABSTRACT 
 
Cryptosporidium parvum infects both humans and animals, and continues to be a 
significant opportunistic pathogen among AIDS patients and one of the leading diarrheal 
pathogens in children. Despite decades of research on cryptosporidiosis including 
screening hundreds of compounds in vitro and in vivo, fully effective therapeutic agents 
are still unavailable. The major goal of this study is to explore three long-chain fatty 
acyl-CoA synthetase (CpACSs) of the parasite as novel drug targets. The molecular and 
biological data showed that the three CpACSs genes are differently expressed in the 
parasite different life cycle stages and their proteins display different subcellular 
distribution patterns in the parasite, suggesting that the those genes may play different 
biological roles in the parasite. Using recombinant proteins, we have determined detailed 
enzyme kinetics for CpACS1 and CpACS2, and observed that the inhibitor triacsin C 
could inhibit their enzyme activities with Ki in the nanomolar range. Triacsin C also 
effectively inhibited the growth of C. parvum parasites in vitro (IC50 = 136 nM). Most 
importantly, triacsin C effectively reduced parasite oocyst production up to 88.1% with 
no apparent toxicity when administered to Cryptosporidium-infected IL-12 knock-out 
mice at 15 mg/kg/d for one week. These observations not only validate CpACSs as a 
pharmacological target, but also indicate that triacsin C and analogs may be explored as 
potential new therapeutics against cryptosporidiosis. 
  
  iii 
DEDICATION 
 
 To Dr. Yuxi Duan, who opened the first door for me to start my scientific career, 
and he is always willing to help me whenever I need it.  
To my parents, Yongxue and Guirong, who always support, encourage and love 
me through my life. 
  iv 
ACKNOWLEDGEMENTS 
. 
I would like express the deepest appreciation to my committee chair, Dr. Guan 
Zhu, for great guidance and support throughout the course of this research. He is always 
available, whenever I need him. I really appreciate his encouragement and friendship. 
Without his supervision and persistent help this dissertation would not have been 
possible. I sincerely thank my committee members, Dr. Jane Welsh, Dr. Yanan Tian, and 
Dr. Sanjay Reddy, for their invaluable advice and support during my graduate career. 
Thanks go to our collaborators, Dr. Jan R Mead and Nina N. McNair, at Emory 
University, for in vivo drug assay.  
Thanks also go to the past and present members in Dr. Zhu Laboratory: Dr. Haili 
Zhang, Dr. Xiangyu Shi, Dr. Mayte Yichoy, Dr. Lixin Xiang, Dr. Mingfei Sun, Dr. 
Yamei Jin, Dr. Jason M. Fritzler, Dr. S. Dean Rider, Lacy Parson, Mary Yu, and Rana 
Eltahan, for their friendly help. I would also like to thank my graduate advisor, Dr. 
Patricia Holman, graduate program coordinators, Stevie Bundy and Katie Cosby, for 
their kind helps. Thanks also go to my friends and colleagues and the department faculty 
and staff for making my time at the Texas A&M University a great experience.  
I also want to thank my parents and parents-in-law, for their support and helping 
taking care of my children. Thanks go to my daughter, Lucy, and my son, Lucas. They 
are filling my life with rainbow colors.  
 A special thank goes to my wife. She has always stood by me, inspired me and 
provided constant encouragement during the entire process.  
  v 
NOMENCLATURE 
 
ABC ATP-Binding Cassette 
ACBP Acyl-CoA Binding Protein 
ACL Acyl-CoA Ligase  
ACP Acyl Carrier Protein  
ACS  Acyl-CoA Synthetase  
AIDS  Acquired Immune Deficiency Syndrome 
AL Acyl-[Acyl Carrier Protein] Ligase  
AMP Adenosine Monophosphate  
AT Acyl-Transferase 
ATP Adenosine Triphosphate  
BI Bayesian Inference  
BLAST  Basic Local Alignment and Search Tool  
BSA  Bovine Serum Albumin  
CD4 Cluster of Differentiation 4 
CD8 Cluster of Differentiation 8 
CDC  Centers for Disease Control and Prevention  
CDS  Coding Sequence  
CoA  Coenzyme A  
COWP  Cryptosporidium Oocyst Wall Protein  
CTP  Cytidine Triphosphate  
  vi 
DAPI  4’,6’-Diamidino-2-Phenyl Indole  
DIC  Differential Interference Contrast  
DMSO  Dimethyl Sulfoxide  
DNA Deoxyribonucleic Acid  
DTNB  5,5’-Dithio-Bis-(2-Nitrobenzoate)  
DTT Dithiothreitol 
EDTA Ethylenediaminetetraacetic Acid 
ER Enoyl-ACP Reductase  
FAS Fatty Acid Synthase 
FBS Fetal Bovine Serum 
FDA Food and Drug Administration 
FITC Fluorescein Iso-Thiocyanate 
gDNA Genomic Deoxyribonucleic Acid 
GTP Guanosine Triphosphate 
HAART  Highly-Active Anti-Retroviral Therapy 
HCT-8  Human Colonic Tumor 8 
HIV Human Immunodeficiency Virus 
ICZN Code of Zoological Nomenclature 
IFN-γ Interferon Gamma 
IL-12  Interleukin 12 
IPTG Isopropyl-1-Thio-β-D Galactopyranoside 
IgY Immunoglobulin Y 
  vii 
LC Long Chain 
KS Ketoacyl-CoA Synthase 
KR  Ketoacyl-ACP Reductase 
MBP Maltose Binding Protein  
MHC Major Histocompatibility Complex 
ML Maximum Likelihood  
MTT Methylthiazol Tetrazolium  
NCBI National Center for Biotechnology Information  
NIH  National Institutes of Health  
NTP Nucleoside Triphosphates  
NTZ Nitazoxanide  
ORF Open Reading Frame 
PAGE Polyacrylamide Gel Electrophoresis  
PBS Phosphate Buffered Saline  
PCR  Polymerase Chain Reaction  
PDB Protein Database 
PEG Polyethylene Glycol 
PKS Polyketide Synthase 
PI Post-Infection  
PP Posterior Probability 
PV Parasitophorous Vacuole  
PVM Parasitophorous Vacuolar Membrane  
  viii 
qRT-PCR Quantitative Reverse Transcriptase-Polymerase Chain Reaction  
RNA Ribonucleic Acid  
rRNA Ribosomal Ribonucleic Acid  
RT-PCR Reverse Transcriptase Polymerase Chain Reaction  
SCID Severe Combined Immune Deficient 
SDS Sodium Dodecyl Sulfate  
SPF Specific Pathogen-Free  
TAMU Texas A&M University  
TBST Tris Buffered Saline containing Tween 20 
TDC Taurodeoxycholic Acid 
TRITC Tetramethyl Rhodamine Iso-Thiocyanate  
UTP Uridine Triphosphate 
VLC  Very Long Chain  
WHO World Health Organization 
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1  INTRODUCTION AND LITERATURE REVIEW 
  
1.1 The history of Cryptosporidium spp. 
Cryptosporidium was first observed in gastric glands of laboratory mice by 
Ernest Edward Tyzzer in 1907 (1). He precisely described its morphology and life cycle. 
The morphology of this protozoan parasite is similar to the coccidia, but lacking 
sporocysts, so that Tyzzer named it as Cryptosporidium muris. In 1912, the second 
species of Cryptosporidium was described in intestine of mouse by Tyzzer, and was 
named as C. parvum (2). For almost 70 years after the discovery, Cryptosporidium was 
regarded as an insignificant pathogen that infected the intestines of vertebrates and 
caused little or no disease. In 1976, the first human cryptosporidiosis was reported as an 
acute, self-limiting illness in an immunocompetent 3-year old child (3). In the same year, 
another human case was reported in an immnunocompromised patient (4). Since then, 
Cryptosporidium started to be recognized as a significant human pathogen. Among the 
first seven cases of human cryptosporidiosis reported between 1976 and 1980, six 
patients were immunosuppressed or immunocompromised, which led to the 
consideration of Cryptosporidium as an opportunistic pathogen (5). From 1976 to 1984, 
the reported cases of human cryptosporidiosis reached to 58, including 18 from 
immunocompetent individuals (6). Therefore, Cryptosporidium was recognized as a 
significant parasitic pathogen that is capable of infecting both immunocompromised and 
immnunocompetent patients. Cryptosporidial infections might result in severe and 
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chronic diarrhea in immunocompromised patients, or mild to severe symptoms but 
usually self-limiting in immunocompetent individuals.  
In the late 1970s and early 1980s, several notable water-borne outbreaks of 
cryptosporidiosis brought more attentions from the government and public on this 
parasite. In 1978, an outbreak of cryptosporidiosis occurred in Carrollton, Georgia, 
United States of America (USA), due to the contamination of a filtered public water 
supply, affected about 13,000 people (7). Two years later, another outbreak in Wiltshire 
and Oxfordshire, UK affected around 5,000 people with 516 diagnosed cases. The most 
massive waterborne outbreak occurred in Milwaukee, Wisconsin, USA in 1993, in 
which estimated 403,000 people had watery diarrhea, and 4,400 people were 
hospitalized. The total costs associated with this outbreak were estimated at $96.2 
million (8,9). Because of the potential of large-scale dissemination with moderate 
illness, and the requirement of specific enhancements of diagnostic capacity and disease 
surveillance, Cryptosporidium is listed as a category B priority agent in the Biodefense 
program by the National Institutes of Health (NIH) and the Centers for Disease Control 
and Prevention (CDC) in the USA (10). The significance in the public health and the 
potential of waterborne outbreaks motivated a substantial research effort to better 
understand the parasites. In the past two decades, studies have greatly expanded our 
knowledge of Cryptosporidium parasites, including taxonomy, epidemiology, 
transmission, host-parasite interaction and molecular biology. One of the milestones in 
the research during this period was the publication of the complete genome sequences of 
C. parvum (Iowa stain) and C. hominis (isolate TU502 isolate), which uncovered their 
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unique biological features characterized by the extremely streamlined metabolic 
pathways and a reliance on the host for nutrients (11,12). Although we have gained 
tremendous knowledge of those parasites from substantial studies, cryptosporidial 
waterborne outbreaks still occur yearly, and fully effective treatments are yet unavailable 
for this disease.  
 
1.2 Taxonomy 
The genus of Cryptosporidium belongs to the Phylum Apicomplexa, in which all 
members possess an apical complex at some stages in their life cycles. Within the 
Apicomplexa, Cryptosporidium is placed under the Class Conoidasida. However, the 
taxonomic relationship of Cryptosporidium under the Class has been under debate since 
last decade (13,14).  Traditionally, Cryptosporidium has been considered as an intestinal 
coccidian because this genus of parasites share similar life cycle development and 
morphology with other coccidian species (15). However, increasing molecular and 
phylogenetic evidences support the fundamental biological differences between 
Cryptosporidium and the Coccidia, which include: (I) the location of Cryptosporidium in 
the host cell is intracellular, but extracytoplasmic; (II) the presence of thick-walled and 
thin-walled oocysts, rather than only thick-walled oocysts (16); (III) the small size of 
oocyst and lack of sporocyst (17); (IV) the lack of apicoplast and its genome (18); and 
(V) the insensitivity to most anticoccidial drugs (19). Recently, molecular phylogenic 
data indicates that Cryptosporidium is an early evolution branch at the base of the 
Apicomplexa, rather than as a sister to the other intestinal and cyst-forming coccidia 
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(14,20,21). Furthermore, phylogenic data of small-subunit rRNA and other genes or 
proteins suggest that Cryptosporidium is more closely related to the gregarines than to 
the coccidia (22). Additionally, the chloroplast-derived apicoplast is present in the three 
major apicomplexan lineages haemospororida, piroplasms and coccidia, but not in 
cryptosporidia and gregarines, suggesting that gregarines and Cryptosporidium might 
have a common ancestor, and apicoplast was lost following the divergence of gregarines 
and Cryptosporidium from other apicompelxans (23,24). A recent genome sequence 
survey (GSS) for Ascogregerina taiwanensis also supports the evolutionary affinity 
between a gregarine and Cryptosporidium (21). However, gregarines possess many 
metabolic pathways that are absent in Cryptosporidium, such as those for de novo 
synthesizing amino acids, pyrimidines, and purines (11,21). 
Currently, there are 25 valid Cryptosporidium species (Table 1.1). In the earlier 
time, mainly oocyst morphology, hosts and infection sites characterized the species of 
Cryptosporidium. Ernest Edward Tyzzer described the first two species, C. muris and C. 
parvum, which were found in mouse gastric glands and small intestines, respectively 
(1,2,17). Those two species are still valid today. However, no new species was reported 
over half century, except that some species in the genus of Sarcocystis were erroneously 
assigned as new Cryptosporidium species (25). The errors were corrected after a unique 
attachment organelle was confirmed as one of the key features to define the 
Cryptosporidium genus in 1960s (25,26). Following this correction, another misleading 
feature, host specificity, was adopted from the coccidian classification system. Based on 
the host origin, multiple new Cryptosporidium species were mistakenly named. Until 
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early 1980s, cross-transmission experiments demonstrated that Cryptosporidium isolates 
could transmit across different host species, which ended the mistakes and many newly 
named species were merged to C. parvum (27-29). Due to lack of effective criteria to 
differentiate Cryptosporidium species, Levine in 1984 considered that only four species 
other than C. parvum were valid, including C. muris in mammals, C. meleagridis in 
birds, C. crotali in reptiles, and C. nasorium in fish (30). 
After the Cryptosporidium was recognized as a significant human pathogen, how 
to differentiate the species of Cryptosporidium became necessary and critical to the 
understanding of parasite transmission and epidemiology (25,31). Because a single 
criterion was insufficient to different Cryptosporidium spp., the combination of several 
criteria was adapted. The genetic markers have been widely applied in defining new 
Cryptosporidium spp., particularly those derived from genes encoding 18S ribosomal 
RNA (rRNA), the hyper-variable 60-kDa glycoprotein (gp60), and the oocyst wall 
protein (COWP) (32,33). Through decades of studies, most researchers have accepted a 
relative stable and practical standard for Cryptosporidium speciation, which include: (I) 
oocyst morphology; (II) genetic characterization; (III) demonstration of natural and, 
whenever feasible, experimentally defined host specificity; (IV) compliance with 
International Code of Zoological Nomenclature (ICZN) (25,31,33). Based on the 
morphological, biological, and molecular data, 25 species of Cryptosporidium have been 
formally described and accepted as valid species (33).Those 25 species include one in 
fish, C. molnari (Alvarez-Pellitero and Sitja-Bobadilla 2002); one in amphibians, C. 
fragile (Jirku M et al. 2008); two in reptiles, C. serpentis (Levine1980) and 
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Table 1.1 The 25 currently confirmed Cryptosporidium species * 
* Data obtained from Una Ryan and Lihua Xiao 2013 (33); ** indicates that those 
species also can infect human. 
Cryptosporidium 
species 
Major 
host(s) 
Site(s) of 
infection 
Oocyst size  
L x W(µm) Reference 
GenBank ID 
(18S rRNA) 
C. molnari Gilthead 
sea bream 
Stomach and 
intestine 4.7 x 4.5 
Alvarez-Pellitero & 
Sitja-Bobadilla 2002 
(34) 
HM243548 
HM243550 
HQ585890 
C. fragile Black-
spined 
toads 
Stomach 
6.2 x 5.5 Jirku M et al.2008(35) 
EU162751-
EU162754 
C. serpentis Amazon 
tree boa 
Stomach 6.2 x 5.3 Levine1980 (36) AF151376 
C. varanii African fat-
tailed geco 
Intestine, 
cloaca 4.7 x 5.0 
Pavlasek et al. 1995 
(37) AF112573 
C. meleagridis** Turkey Intestine 4.3 x 4.9 Slavin 1955 (38) AF112574 
C. baileyi Chicken Cloaca, bursa, 
trachea 6.4 x 4.8 
Current et al. 1986 
(39) L19068 
C. galli Chicken Preventriculus 8.3 x 6.3 Pavlasek 1999 (33) AF316624, AY18847 
C. muris Rodents Stomach 8.4 x 6.1 Tyzzer 1907 (1) AB89284 
C. parvum Cattle, 
sheep, 
human 
Small intestine 
4.4 x 4.9 Tyzzer 1912 (2) AF308600 
C. wrairi Guinea 
pigs 
Small intestine 4.6 x 5.4 Vetterling et al. 1971 (40) AF115378 
C. felis** Cats Small intestine 4.5 x 5.0 Iseki 1979 (41) AF108862 
C. andersoni Cattle Abomasum 5.5 x 7.4 Lindsay et al. 2000 (42) AF093496 
C. canis** Dogs Small intestine 4.8 x 5.0 Fayer et al. 2001 (43) AF112576 
C. hominis Humans Small intestine 4.8 x 5.2 Morgan-Ryan et al. 2002 (44) AF108865 
C. suis Pigs Intestine 4.2 x 4.6 Ryan et al 2004 (45) AF115377 
C. bovis Cattle Small intestine 4.6 x 4.9 Fayer et al. 2005 AY741305 
C. fayeri Marsupials Small intestine 4.3 x 4.9 Ryan et al. 2008 (46) AF159112 
C. macropodum Marsupials Small intestine 4.9 x 5.4 Power and Ryan 2008 (47) AF513227 
C. ryanae Cattle Small intestine 3.7 x 3.2 Fayer et al. 2008 (48) AY587166 
C. xiaoi Sheep Small intestine 3.9 x 3.4 Fayer & Santin 2009 (49) EU408314 
C. ubiquitum** Sheep Small intestine 4.9 x5.2 Fayer et al. 2010 (50) AF2622328 
C. cuniculus Rabbits Small intestine 5.4 x 6.0 Robinson et al. 2010 (51) FJ262725 
C. tyzzeri Mice Small intestine 4.6 x 4.2 Ren et al. 2012 (52) AF112571 
C. viatorum Humans Small intestine 4.7 x 5.4 Elwin et al. 2012 (53) HM485434 
C. scrofarum Pigs Small intestine 4.8 x 5.2 Kvac et al. 2013 (54) EU331243 
  7 
 
C. varanii (Pavlasek et al. 1995); three in birds, C. meleagridis (Slavin 1955), C. baileyi 
(Current et al. 1986), and C. galli (Pavlasek 1999); eighteen in mammals, C. muris 
(Tyzzer 1907), C. parvum (Tyzzer 1912), C. wrairi (Vetterling et al. 1971), C. felis 
(Iseki 1979), C. andersoni (Lindsay et al. 2000), C. canis (Fayer et al. 2001), C. hominis 
(Morgan-Ryan et al. 2002), C. suis (Ryan et al 2004), C. bovis (Fayer et al. 2005), C. 
fayeri (Ryan et al. 2008), C. macropodum (Power and Ryan 2008), C. ryanae (Fayer et 
al. 2008), C. xiaoi (Fayer and Santin 2009), C. ubiquitum (Fayer et al. 2010), C. 
cuniculus (Robinson et al. 2010), C. tyzzeri (Ren et al. 2012), C. viatorum (Elwin et al. 
2012), C. scrofarum (Kvac et al. 2013) (25,31,33) (Table 1.1). Additionally, there are 
over 40 genotypes that require more morphological, biological, and molecular data to 
determine whether they are valid new species (33).  
 
1.3 Morphology and life cycle 
The whole life cycle of Cryptosporidium spp. contains 6 developmental stages. 
Various stages have different morphological features as revealed by light and electron 
microscopic studies.  
1.3.1 Oocysts 
 The oocysts of Cryptosporidium spp. are round to oval in shape, with sizes 
ranging from 3.7 to 8.4 µm in length and 3.2 to 6.3 µm in width (17,48). Oocysts are 
resistant to chlorine at concentrations typically used in water treatment (55), which is 
mainly due to its tough, durable oocyst wall structure. Cryptosporidium oocyst wall has 
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four layers, including an outer electron-dense layer (8.5 ± 0.6 nm), a translucent middle 
layer (4.0 ± 0.2 nm), and two inner electron-dense layers (13.0 ± 0.5 nm and 18.6 ± 1.6 
nm, respectively) (56,57). A special suture structure is embedded in the inner layers, 
which will open during excystation to release sporozoites (56). Each mature oocyst 
contains four sporozoites, and one membrane-enclosed residual body with large lipid 
body inside.  
1.3.2 Sporozoites and merozoites 
Sporozoites and merozoites are two infectious cell forms, which can invade host 
cells to start the infection. Sporozoites are contained in mature occysts and released by 
an excystation process after appropriate hosts ingests them. Merozoites are formed in 
meront developed in host cells, and will be released when meront are mature. 
Sporozoites and merozoites are morphologically similar, crescent in shape, with the 
anterior end slightly pointed and the posterior end rounded. In the anterior region, there 
is an apical complex consisting of a set of organelles including apical rings, conoids, 
rhoptries, micronemes, and electron-dense granules.  
1.3.3 Trophozoies 
Trophozoites are transitional forms from sporozoites or merozoites to meronts. 
After sporozoites or merozoites attach and invade into host cells, the parasites become 
spherical, which are called trophozoites. Trophozoites are round or oval shaped and vary 
in size ranging from 2.0 to 2.5 µm (58). During the formation of a trophozoite, its apical 
complex starts to disappear, and parasitophorous vacuole membrane (PVM) extends 
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from host cell cytoplasmic membrane until it fully covers the trophozoite. In the 
trophozoite stage, a unique feeder organelle is formed above the electron-dense 
attachment zone at the contact site in host cells. Another significant character of 
trophozoite is the large nucleolus (1.0 - 1.3 µm in diameter) within a large nucleus 
(57,58).  
1.3.4 Meronts 
Cryptosporidial trophozoites will undergo asexual cell cycle (merogony) to form 
multinuclear meronts. The first generation of meronts derived from sporozoites are type 
I meronts. Merozoites exit from type I meronts, re-infect new host cells, and develop 
into either type I or type II meronts. Both types I and II meronts are morphological 
similar (4-5 µm in diameter), except that a mature type I meront produces 6 or 8 
merozoites, while a type II meront typically contains 4 merozoites (16). Type I 
merozoites may enter one or more cycles of mergony before developing into type II 
meronts.  
1.3.5 Gamonts and gametes 
Type II merozoites invade new host cells and undergo sexual development to 
form gamonts (59). Gamonts further develop into microgamonts (male) or 
macrogamonts (female). A microgamont has a very compact nucleus and lacks rhoptries, 
which differentiates it from a meront (16). Mature microgamont may contain up to 16 
bullet-shaped microgametes, which have slightly expanded anterior ends and relatively 
big nuclei. Unlike microgamonts, a mature macrogamont contains only one 
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macrogamete. An early stage of macrogamont is morphologically similar to a 
trophozoite, and possesses a large nucleus and a feeder organelle (60). However, a later 
stage of macrogamont is ultrastructurally distinguishable from other developmental 
stages by possessing amylopectin-like bodies near the feeder organelle, and oocyst wall 
forming bodies (16). 
 
1.4 Life cycle 
Cryptosporidium species complete their life cycle in a single host including both 
sexual and asexual developments. There are six major development stages as described 
above, among which only the oocyst is an exogenous stage for the transmission of 
parasites between hosts (16,60) (Figure 1.1).  
The infection is acquired when a susceptible host ingests oocysts from 
contaminated food or water. The excystation occurs when ingested oocysts are exposed 
to suitable environmental factors, such as appropriate pH, temperature, pancreatic 
enzymes, and bile salts (61,62), by which infective sporozoites are released from oocysts 
through an open suture in the oocyst wall (63). The released motile sporozoites will 
rapidly attach to and invade gastrointestinal epithelial cells to start intracellular 
development. During invasion, the sporozoite is encapsulated by host cell membrane that 
forms a parasitophorous vacuole (PV), in which it develops into a spherical-shaped 
trophozoite (64,65). The trophozoite enters first generation of merogony to form type I 
meront containing 8 to 16 haploid merozoites. Released type I merozoites infect 
neighbor host cells to enter second generation of merogony, forming type II meront  
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Figure 1.1 Life cycle of Cryptosporidium parvum (Reproduced from 
http://www.cdc.gov/parasites/crypto/biology.html). The infection begins with the 
ingestion of thick-walled oocysts by host. Following excystation in host intestine, 
sporozoites (a) attach and invade the epithelia cells to form trophozoite (b). Trophozoite 
develops to type I meront(c), and eight type I merozoites (d) release from mature 
meront. Type I merozoite infects the epithelia cells, which either develops to type I 
meront again or to type II meront (e) with four merozoites. The sexual stage starts with 
type II merozoite (f) invading host cells, and then forming macrogamont (male) (h) and 
microgamont (female) (g). Upon the fertilization between macrogamont and 
micorgamete that released from microgamont, a zygote (i) forms and then develops into 
oocyst. Thin-walled oocysts (j) can directly excyst and cause autoinfection. Thick-
walled oocysts (k) are excreted from the host with feces, which may cause water and 
food contamination.  
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containing four merozoites. Type II merozoites invade new host cells and initiate sexual 
reproduction to form either microgamonts or macrogamonts. Microgametes, which 
developed in the microgamonts, are released to search for uninucleate macrogamonts. 
Fertilization between micro- and macro-gametes forms zygotes that are the only diploid 
cells in the complex life cycle of Cryptosporidium. A zygote immediately undergoes 
sporogony to form an oocyst containing 4 haploid sporozoites. There are thick- and thin-
walled oocysts. Approximately 80% of the oocysts have a thick, two-layer wall. These 
thick-walled oocysts are released into the environment. The other 20% of the oocysts 
contain one layer thin-wall, which can be ruptured to release sporozoites within the same 
host, causing auto-infection. The auto-infection of sporozoites from thin-walled oocysts 
and repetitive type I merogonic development are responsible for the persistent and 
chronic infections, particularly in immune-deficient individuals without repeated 
exposure to the environmental oocysts (16). 
 
1.5 Cryptoporidiosis 
Cryptosporidiosis is a common diarrheal illness caused by Cryptosporidium 
infection. Cryptosporidium typically infects epithelial cells in the microvillus border of 
the gastrointestinal tract of all classes of vertebrates, including fishes, amphibians, 
reptiles, birds and mammals. Although a number of Cryptosporidium species can infect 
humans, C. parvum and C. hominis are the two major human pathogens. 
Cryptosporidiosis is generally self-limiting in immunocompetent individuals (66). 
However, it may result in fulminant and/or chronic diarrhea, or even death in 
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immunocompromised patients, as well as persistent infections and stunted mental 
development in children (67,68). In developing countries Cryptosporidium is one of the 
four leading diarrheal pathogens in children under 2 years of age (69). Moreover, 
cryptosporidiosis is highly associated with malnutrition in children or even mortality in 
toddlers, and the infections in infants and toddlers are also linked to impairing of growth, 
physical fitness, and cognitive function in late childhood (69-71). 
 
1.6 Host immune responses 
The host immune system plays a critical rule in controlling the pathological and 
clinical outcomes associated with the Cryptosporidium infections. Cryptosporidiosis is 
usually self-limiting in immunocompetent individuals, but can be chronic and life-
threatening in immunocompromised patients, which suggests that host immune status is 
critical in eliminating Cryptosporidium infections. Although both innate and adaptive 
immune responses in humans and animals are involved, innate immunity alone appears 
to be insufficient to protect hosts from cryptosporidial infections (72,73). Here we will 
highlight the roles of major immune factors in response to cryptosporidial infections in 
humans and animals. 
1.6.1 CD4+ and CD8+ T cells 
Several studies have suggested that CD4+ T cells are the most important cells in 
the immune response to Cryptosporidium infection. The clinical outcome of 
cryptosporidiosis is highly correlated to the CD4+ cell count. In human patients whose 
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CD4+ cell counts are over 180 cells/µl, including those carrying immunodeficiency virus 
(HIV), cryptosporidiosis is generally self-limited. However, in patients with lower CD4+ 
cells counts (e.g., <50 cells/µl), such as AIDS patients, the infection become chronic and 
life-threatening (72,74). Furthermore, the rapid increase of mucosal CD4+ cells is 
associated with the clearance of intestinal cryptosporidiosis in a HIV-infected patient 
during highly active antiretroviral therapy (75). Similar results have also been observed 
in mice. Cryptosporidial infections in nude mice (T cell deficient) are chronic, 
suggesting that T cells are required for the recovery from Cryptosporidium infection 
(76). Mice with severe combined immunodeficiency (SCID) lack both CD4+ and CD8+ 
T lymphocytes and experience persistent life-threatening cryptosporidial infectious after 
inoculated with C. parvum oocysts. When SCID mice were transfered with complete 
lymphocyte populations (containing both CD4+ T and CD8+ T cells), or CD4+ T cells 
alone, or CD8+ T cells alone, followed by challenges with C. parvum, only those 
received both CD4+ and CD8+ cells, or CD4+ cells alone, but not those received CD8+ 
cells alone, could recover from persistent cryptosporidial infections (77-79). Those 
results suggest that CD4+ T cells, but not CD8+ T cells, are necessary for the eradiation 
of established C. parvum infection. Similarly, the depletion of CD4+ cells in 
immunocompetent mice exacerbated the C. parvum or C. muris infections (80,81). The 
significance of CD8+ T cells in control of cryptosporidiosis is less clear than CD4+ T 
cells. Some studies showed that CD8+ T cells were not required for control of 
cryptosporidiosis, while others suggested they might play some non-essential roles in 
this process. For example, in major histocompatibility complex (MHC) class-I deficient 
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mice that lacked functional CD8+ T cells, investigators observed a similar level of C. 
parvum infection to that in wild-type mice (82). On the other hand, another study 
showed that the depletion of CD8+ cells from donor spleen cells delayed the recovery of 
the reconstituted SCID mice from parasites infection (78). Additionally, the depletion of 
CD8+ cells could reduce the level of protection to C. muris infection, and the blocking of 
CD8+ cells with antibodies could increase C. muris oocyst shedding in mice (80). 
1.6.2 B cells 
The roles of B cells and antibodies in cryptosporidiosis are still not fully 
understood. The correlation between selective IgA deficiency and persistent 
cryptosporidial infection indicated that B cells contributed to the elimination of parasites 
(83). The high serological responses to a 27-kDa Cryptosporidium-antigen was 
associated with a reduced risk of diarrhea in both HIV-negative and HIV-positive 
patients, also suggesting that antibodies played protective roles (84,85). However, some 
other evidence indicated that antibodies might not play an essential role to protect host 
from or eliminate Cryptosporidium infection. For example, Cryptosporidium-specific 
antibody levels seemed to be uncorrelated to the diarrheal symptom (86). High levels of 
parasite-specific antibodies were also present in AIDS patients with chronic 
cryptosporidiosis (87). The nonessential roles of B cells in the recovery from 
Cryptosporidium infection were also observed in mice (88,89).  
  17 
1.6.3 IFN-γ  
A number of studies using SCID and nude mice suggested that IFN-γ played a 
major role in the innate immunity against C. parvum infections. Both SCID and nude 
mice were relatively resistant to C. parvum infection, but treatment with anti-IFN-γ 
neutralizing antibodies could significantly decrease the resistance, indicating that IFN-γ 
was involved in a T-cell-independent immune response to the parasite infection (78,81). 
Similarly, C. parvum infections were much heavier in IFN-γ knockout SCID mice than 
parent SCID mice (90). 
IFN-γ is also a key player in adaptive immune responses. An in vitro study 
showed that CD4+ T-cells purified from C. parvum immunized mice could produce IFN-
γ upon incubation with C. parvum antigen (91). Treatment of normal BALB/c mice with 
anti-IFN-γ antibodies greatly increased reproduction of C. parvum oocysts, although 
infection was self-limited (81). Additionally, IFN-γ knockout adult BALB/c mice 
developed moderate C. parvum infection and recovered later, whereas infection in IFN-γ 
knockout adult C57BL/6 mice could be overwhelming and might cause death within two 
weeks after infection (92,93). Furthermore, the high levels of IFN-γ in the intestines 
were associated with the recovery from C. parvum infection in neonatal mice (94), 
calves (95,96), and humans (97).  
1.6.4 IL-12 
Interleukin 12 (IL-12) is another important cytokine that induces NK cells and T 
cells to produce INF-γ (98) in response to the C. parvum infection. Treating 
immunocompetent or immunodeficient neonatal BALB/c mice with a single dose of IL-
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12, one day before the inoculation with C. parvum oocysts, prevented the establishment 
of infection (99). The protective role of IL-12 was associated with IFN-γ production. 
The IL-12 treatment increased the levels of IFN-γ mRNA in the intestines, and injection 
of anti-IFN-γ antibodies into mice two days prior to the IL-12 treatment completely 
blocked the protective effect of IL-12 against C. parvum infection (99). In the early stage 
of infection in BALB/c mice, anti-cryptosporidial resistance was associated with the 
strong expression of IL-12 and IFN-γ mRNA in the intestines (100). Furthermore, C. 
parvum infections would result in acute diseases in the IL-12 knockout adult C57BL/6 
mice, though the mice were able to fully recover within 2 weeks, whereas infections 
could not be established in the wild-type adult mice (101). Therefore, IL-12 knockout 
C57BL/6 mice are also used as a model for testing drug efficacies against acute 
cryptosporidiosis. 
 
1.7 Treatments 
In the past few decades, at least hundreds of chemo- and immunotherapeutic 
agents have been tested in vitro or in vivo for their anti-cryptosporidial efficacies, and 
some of them have been tested in clinical trials (102). However, fully effective anti-
cryptosporidiosis drugs are still not available today. Currently, only nitazoxanide is 
approved by FDA to treat cryptosporidiosis in immunocompetent patients, but its 
efficacy is still under debate. Here we will briefly review the current status of anti-
cryptosporidial drug development as well as the recommended treatments and 
medicines. 
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1.7.1 Highly-active anti-retroviral therapy 
Although highly-active anti-retroviral therapy (HAART) is an aggressive 
treatment regimen to suppress HIV viral replication and the disease progression, 
HAART could also markedly decrease occurrence of opportunistic infections including 
cryptosporidiosis in AIDS patients. Since the introduction of HAART in 1996, the 
mortality and morbidity caused by opportunistic pathogens in AIDS patients have 
decreased dramatically in developed countries (103). An earlier survey of 6,941 HIV-
infected individuals in Europe and Australia showed that cases of cryptosporidiosis 
decreased over 15 times since HAART was available (1997 - 2001) in comparison with 
those in the pre-HAART era (1994-1996) (104). HAART can improve cryptosporidiosis 
symptoms and even completely eradiate the parasite from AIDS patients. The anti-
cryptosporidial effect of HAART was associated with the reconstruction of cellular 
immunity and the increase of CD4+ T-cells (103). In addition to rebuilding host 
immunity, protease inhibitors used in HAART also displayed certain chemotherapeutic 
effect against Cryptosporidium infection (105-107). Protease inhibitors in HAART are 
known to target HIV-1 aspartyl protease, but their therapeutic mechanism against 
Cryptosporidium is yet unclear. 
1.7.2 Paromomycin 
Paromomycin is a non-absorbable aminoglycoside with broad spectrum of 
antimicrobial activity, which is mainly used to treat Giardia and amoebic intestinal 
infectious. In the early 1990s, the anti-cryptosporidiosis activity of paromomycin was 
reported in a number of studies (108-111). Since then, paromomycin was widely used to 
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treat cryptosporidiosis in HIV-infected patients. However, a later study on 35 AIDS 
patients indicated that paromomycin did not show better efficacy than placebo in treating 
symptomatic cryptosporidial enteritis (112). Paromomycin is still considered as an 
option to treat cryptosporidiosis in AIDS patients in many countries, although it is not 
“officially” approved by FDA. Because of the clinical significance of cryptosporidiosis, 
paromomycin may be used in adult AIDS patients along with HAART, but is not 
recommended to be used alone without HAART (http://aidsinfo.nih.gov/guidelines) 
(113). 
1.7.3 Nitazoxanide 
Nitazoxanide is the only FDA-approved drug for treating cryptosporidiosis in 
patients with a healthy immune system, but not in immunocompromised individuals. In 
an earlier study, administration of nitazoxanide for 3 days at 500 mg for adults or 10 mg 
for children twice daily significantly reduced the duration of both diarrhea and oocyst 
shedding in immunocompetent patients in comparison to placebo (114). Among AIDS 
patients, nitazoxanide was effective in eradicating C. parvum and resolving the 
associated diarrhea in adults (115), but ineffective in children in two randomized trials, 
even with high doses and prolonged treatments (116,117).  
The introduction of HAART has tremendously decreased the negative effects of 
cryptosporidiosis on the HIV-infected patients in developed country. However, 
development of new inexpensive and effective therapeutics for cryptosporidiosis is still 
necessary. First, the availability of antiretroviral drugs is highly limited in the low and 
middle-income countries. In 2012, the World Health Organization (WHO) estimated that 
  21 
only 33% of children (0 - 14 years old), among eligible for receiving HAART treatment 
groups, have received HAART in the 22 priority countries in the Global Plan of WHO 
(118). Second, cryptosporidiosis is one of the main causes of diarrhea in young children 
that is independent on the HIV infections (119). Cryptosporidial infections in children 
could result in impaired physical fitness in late childhood (120), or even childhood 
deaths as reported in sub-Saharan Africa (121). Third, Cryptosporidium frequently 
causes water-borne outbreaks, and is listed as a Category B priority pathogen in the 
Biodefense program in the United States. Fully effective treatments are urgently needed 
when massive cryptosporidiosis outbreaks occur. Development of effective 
chemotherapy for cryptosporidiosis is particularly necessary in developing countries, in 
which chronic diarrhea and malnutrition caused by cryptosporidiosis are common in 
children. 
 
1.8 Fatty acid metabolism in Cryptosporidium 
The availability of the whole genomes of C. parvum and C. hominis has greatly 
contributed to our understating of Cryptosporidium metabolism. The annotation and 
analysis of their whole genomes have revealed a highly streamlined metabolism in these 
two major human Cryptosporidium species. More importantly, Cryptosporidium are 
unable to synthesize most nutrients de novo, including amino acids, nucleotides and fatty 
acids. Additionally, Cryptosporidium lacks a plastid-derived apicoplast as well as the 
mitochondrial genome and associated metabolic pathways (11,12,18). Therefore, many 
well-studied drug targets in other apicomplexans are absent in Cryptosporidium.  
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The lack of typical drug targets is one of the major reasons for the remarkable 
insensitivity of Cryptosporidium to various antimicrobial agents. However, a number of 
unique drug targets in different metabolic pathways have been proposed and 
investigated, such as the synthesis of longer isoprenoid using 5-carbon isoprene units 
(122), dihydrofolate reductase (123), pyrimidine salvaging enzymes (124), inosine 
monophosphate dehydrogenase (125), and fatty acids metabolic pathways (126). In this 
section, we will highlight the major features of fatty acid metabolism in 
Cryptosporidium. 
Fatty acid metabolism in C. parvum is highly simplified, featured by the lack of 
de novo fatty acid synthesis and β-oxidative pathway. However, this parasite possesses a 
number of other enzymes involved in lipid metabolism, including those involved in fatty 
acids activation and elongation, and synthesis of complex lipids (127,128). This parasite 
possesses two fatty acid elongation systems, namely type I fatty acid synthase (CpFAS1) 
and long chain fatty acid elongase system. CpFAS1 is a 25-kb intronless gene that 
encodes a multifunctional polypeptide compromised of at least 21 enzymes domains, 
including N-terminal loading unit containing an acyl-ligase (AL) and an acyl-carrier 
protein (ACP), C-terminal reductase (R) domain, and three internal acyl-elongation 
modules (129,130). Each internal acyl-elongation module contains a complete set of 6 
enzymes including ACP, acyl-transferase (AT), ketoacyl-CoA synthase (KS), ketoacyl-
ACP reductase (KR), hydroxyacyl-ACP dehydrase (DH), and enoyl-ACP reductase (ER) 
for the elongation of two-carbon units (131). Biochemical data demonstrated that N-
terminal AL domain and C-terminal reductase had a substrate preferences towards long 
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chain fatty acids and very long chain fatty acyl-chains, separately, indicating that the 
CpFAS1 is involved in fatty acid elongation rather than de novo synthesis of fatty acids 
(129,131). In addition to CpFAS1, C. parvum possesses another fatty acid elongation 
system that uses fatty acyl-CoA thioesters rather than fatty acyl-ACP as substrates. All 
enzymes involved in the elongation of fatty acyl-CoA thioesters are present in the C. 
parvum genome, including β-ketoacyl-CoA synthase (cgd8_4630),  β-ketoacyl-CoA 
reductase (cgd3_2370), β-hydroxyacyl-CoA dehydratase (cgd3_2150) and trans-2-
enoyl-CoA reductase (cgd2_1200) (132). The biochemical features of β-ketoacyl-CoA 
synthase (also known as fatty acyl elongase) in C. parvum have been characterized using 
recombinant protein expressed in HEK-293T cells. This elongase was capable of adding 
a single two-carbon unit to long chain fatty acyl-CoA thioesters with a substrate 
preference towards myristoyl-CoA (C14:0) and palmitoyl-CoA (C16:0) (133).  
A long-type fatty acyl-CoA binding protein (ACBP) has also been identified in 
C. parvum. ACBP may function as an acyl-CoA ester carrier and responsible for 
intracellular movement of activated fatty acids or restraining them to prevent free acyl-
CoA esters from disrupting cell membranes. Although ACBPs are capable of binding 
medium- to long-chain fatty acyl-CoA esters, different ACBPs have their own substrate 
preferences and binding affinities. In line with C. parvum elongase, CpACBP also 
prefers to binding to long chain and very long chain fatty acyl-CoA (127). 
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Figure 1.2 Comparison of amino acid sequences at the two conserved signature motifs 
of ACSs from C. parvum and other species. Highly conserved amino acids are 
highlighted in yellow. Position of the first and last residues is indicated. Identical and 
highly similar amino acids are marked by asterisks (*), and dots (.), respectively. 
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Figure 1.3 Illustration on the role of ACS in the fatty acid metabolism in C. parvum. 
The parasite is incapable of synthesizing fatty acids de novo, thus relying on salvaging 
them from the environment or host cells. Fatty acids cross the biomembranes either by 
unknown transporters and/or coupled with acylation by ACS, or by passive diffusion. 
Free fatty acids need to be activated by ACS to form fatty acyl-CoA before they enter 
subsequent metabolism pathways, including further chain elongation by elongase (ELO), 
synthesis of complex lipids and membrane remodeling. Inhibition of ACS function (such 
as by triacsin C) may completely block these pathways, thus killing the parasite. 
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C. parvum also possesses three long chain fatty acyl-CoA synthetases (CpACSs; 
also known as fatty acid-CoA ligases, ACLs) [EC 6.2.1.3] that catalyze the 
thioesterification between free fatty acids and CoA to form fatty acyl-CoAs (134). 
Virtually all fatty acids need to be activated to form fatty acyl-CoAs before they can 
enter subsequent metabolic pathways, such as the synthesis of complex lipids and the 
degradation of fatty acids via the β-oxidation (135). Fatty acyl-CoAs are also involved in 
other biological processes such as protein modification (136,137), cell proliferation 
(138), intracellular protein transport (139), and cell signaling (140,141). Some ACSs are 
involved in fatty acid transport into cells by the process of vectorial acylation (142,143). 
Therefore, ACSs are indispensible in all organisms and may serve as good drug targets. 
All of the three CpACSs contain a highly conserved AMP/ATP binding motif 
and an ACS signature motif essential to the ACS activity (142,144) (Figure 1.2). ACS 
proteins from different taxonomic groups, such as those from humans (e.g., P33121), 
yeast (e.g., P30624) and bacteria (e.g., P69451), share less than 50% similarities. Based 
on the C. parvum and C. hominis genome information and related studies, CpACSs 
might be involved in salvaging fatty acids from environment and/or from host cells as 
some ACSs in bacteria and yeast (145,146). Their products would be routed to many 
critical metabolic pathways including the fatty acid elongation, lipid synthesis, 
membrane remodeling, and lipid droplet forming (128,147) (Figure 1.3). Therefore, we 
hypothesize that targeting CpACSs may have the potential to block all downstream 
reactions using fatty acids as substrates, thus inhibiting the parasite growth.  
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To test the hypothesis, we have studied the molecular and biochemical features 
of CpACSs. We have also tested the effect of a potent ACS inhibitor, triacsin C, on 
CpACS1 and CpACS2 enzyme activities, as well as its efficacy against parasite 
development in vitro on HCT8 cells and in vivo in an IL-12 knockout mouse model 
representing acute cryptosporidiosis. 
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2 LONG CHAIN FATTY ACYL-COENZYME A SYNTHETASES AS NOVEL 
DRUG TARGETS IN CRYPTOSPORIDIUM PARVUM* 
 
2.1 Overview 
C. parvum is a unicellular zoonotic pathogen that can cause severe watery 
diarrhea in both humans and animals (66). Cryptosporidial infections in 
immunocompromised individuals can be prolonged and life threatening. However, in the 
United States, FDA-approved treatments remain unavailable to treat this opportunistic 
infection in AIDS patients, whereas only nitazoxanide is approved for use in 
immunocompetent individuals. Therefore, there is an urgent need for new drugs, 
particularly those that can be safely used in immunocompromised people. The slow 
progress in developing anti-cryptosporidial drugs is largely due to the unique metabolic 
features in this parasite, which are represented by a highly streamlined metabolism and 
inability to synthesize nutrients de novo (11,18). In addition, as previously mentioned, 
this parasite is metabolically different from other apicomplexans by lacking many 
important pathways, including type II fatty acid synthase (FAS), isoprenoid synthesis, 
the cytochrome-based respiratory chain and the citrate cycle (11). Therefore, many 
classic drug targets are not effective against Cryptosporidium. So, there is an urgent need 
                                                
* Part of this research was reprinted from Fengguang Guo, Hiali Zhang et al. 2014,  
Amelioration of Cryptosporidium parvum Infection In Vitro and In Vivo by Targeting 
Parasite Fatty Acyl-Coenzyme A Synthetases. Journal of Infectious. Disease. 209(8): 
1279-1287, with permission from Oxford University Press. It is available online at: 
http://jid.oxfordjournals.org/content/209/8/1279.long.  
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to identify novel drug targets which can be used to develop new anti-Cryptosporidium 
drugs, particularly new drugs for AIDS patients. 
However, some essential core metabolic pathways, including energy metabolism 
and lipid synthesis are present in this parasite. Many essential enzymes within these 
pathways may serve as new drug targets because they are either absent in, or highly 
divergent from those in humans and animals. Within lipid metabolic pathways, [AMP-
binding]-long chain (LC) and very long chain (VLC) fatty acyl-CoA synthetases (ACSs; 
aka, fatty acid-CoA ligases, ACLs) [EC 6.2.1.3] are a large family of enzymes that 
catalyze the thioesterification between free fatty acids and CoA to form fatty acyl-CoAs 
via a two-step reaction (Figure 2.1) (134). ACS may also function as fatty acid 
transporters in some organisms (142,143). ACS is indispensible in all organisms because 
fatty acids have to be activated by this enzyme to form acyl-CoA thioesters before they 
can enter various catabolic and anabolic pathways. Fatty acyl-CoA thioesters serve as 
key intermediates in the biosynthesis of cellular lipids and in energy metabolism via β-
oxidation (135). Additionally, acyl-CoAs are also involved in some biological processes 
such as protein modification (136,137), cell proliferation (138), intracellular protein 
transport (139), and cell signaling (140,141).   
The C. parvum genome encodes three LC-ACSs (named CpACS1, CpACS2 and 
CpACS3), which differs from other apicomplexans such as Plasmodium falciparum that 
possesses at least 11 ACS genes (148). In the present study, we have cloned and 
engineered all three CpACS genes into the pMAL-c2x vector. We successfully 
expressed recombinant CpACS1 and CpACS2 as maltose-binding protein (MBP)-
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fusions proteins and analyzed their biochemical characters. We provided detailed 
enzyme kinetics and demonstrated that triascin C, a potent ACS inhibitor, not only 
inhibited CpACS enzyme activity, but also displayed satisfactory efficacies against C. 
parvum growth both in vitro and in vivo. 
 
2.2 Materials and methods 
2.2.1 General procedures for manipulating C. parvum and isolating nucleotide acids 
The IOWA-1 strain of C. parvum maintained by infecting calves was purchased 
from Bunch Grass Farm (Deary, ID) and only fresh oocysts (≤3 months old since 
harvest) were used in this study. Oocysts were purified from calf feces by a sucrose-
gradient centrifugation protocol, followed by treatment with 10% Clorox on ice for 7 
min, and repeatedly washing by centrifugation in sterile water for 5-8 times (149,150). If 
minor debris was still present, oocysts were further purified by a Percoll-gradient based 
method and resuspended in phosphate-buffered saline (PBS) before use. For the 
preparation of free sporozoites, oocysts were excysted in PBS containing 0.25% trypsin 
and 0.75% taurodeoxycholic acid for 1 h at 37 °C. Sporozoites were washed 2-3 times 
with HBSS and concentrated as previously described (151). 
For in vitro experiments, a human ileocecal epithelial cell line (HCT-8, ATCC # 
CCL-225) was seeded into 24-well cell culture plates and cultured at 37 °C in RPMI 
1640 medium (Sigma-Alderich) containing 10% fetal bovine serum (FBS) under an 
atmosphere of 5% CO2 until they reached to ~80% confluence. Purified C. parvum 
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oocysts were added into the cell culture, typically at a parasite:host cell ratio of 1:2 (i.e., 
105 oocysts/well) or as specified, and allowed to infect host cells for 3 h. Parasites that 
failed to invade host cells were removed by a medium exchange. Intracellular parasites 
were allowed to grow for specified time periods before subsequent experiments 
including RNA isolation for expression analysis or fixation for immunofluorescence 
staining.  
For the cloning of CpACS genes, genome DNA (gDNA) was isolated from 
oocysts or sporozoites using DNeasy Blood & Tissue Kit (Qiagen Inc., Valencia, CA). 
For gene expression analysis and qRT-PCR-based in vitro drug testing, total RNA was 
isolated from oocysts, free sporozoites or intracellular parasites developed in host cells at 
specified times using Qiagen RNeasy Mini Kit as described (150). 
2.2.2 Sequence analysis 
Phylogenetic relationships of CpACS proteins with other orthologs within the 
chromalveolates were determined by maximum likelihood (ML) and Bayesian inference 
(BI) methods. ACS orthologs were retrieved from NCBI protein databases by repeated 
BLAST searches using ACS protein sequences from C. parvum and other 
apicomplexans as queries. Multiple sequence alignments were performed using 
MUSCLE v3.8.31 program (http://www.drive5.com/muscle/). Identical sequences and 
short partial sequences were removed, and only amino acid positions that could be 
unambiguously aligned were used in phylogenetic reconstructions. The final dataset 
consisted of 120 taxa with 281 amino acid positions. In ML analysis, bootstrapping 
supporting values were derived from 1000 replicated sequences using TreeFinder 
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program (version 2008) (http://www.treefinder.de). BI analysis used MrBayes program 
(v3.2.1) (http://mrbayes.sourceforge.net/), in which 106 generations of searches were 
performed with two independent runs, each run with 4 chains running simultaneously. 
Posterior probability (PP) values were derived after the first 25% trees were discarded. 
Both ML and BI analyses used WAG amino acid substitution model, with the 
consideration of the fraction of invariance (Finv) and a 4-rate gamma distribution among 
varied sites (Γ [4-rate]) for among-site heterogeneity (i.e., Finv + Γ [4-rate] + WAG). 
Consensus trees were displayed using FigTree (v1.3.1) program 
(http://tree.bio.ed.ac.uk/software/figtree/), and final annotation was performed using 
Adobe Illustrator CS4 program. 
Sequence logos for the conserved motifs were derived from the 120 aligned 
chromalveolate sequences using WebLogo3 server (http://weblogo.threeplusone.com). 
Potential signal peptides were analyzed at SignalP 4.1 server 
(http://www.cbs.dtu.dk/services/SignalP/) using model for eukaryotes. 
2.2.3 Quantitative analysis of CpACS gene expressions 
The relative expression levels of CpACS1, CpACS2 and CpACS3 genes in 
oocysts, sporozoites and intracellular parasite developed in HCT-8 cells for 6 h to 72 h 
were evaluated by quantitative real-time RT-PCR (qRT-PCR) using One-Step RT-PCR 
QuantiTect SYBR Green RT-PCR Kit (Qiagen). The levels of C. parvum 18S rRNA 
(Cp18S) were used as the internal standard for normalization as previously described 
(152). Each of the qRT-PCR reaction contained 0.5 µM of primers, 1 ng of total RNA 
from oocysts and sporozoites or 15 ng total RNA from intracellular parasites in 20 µL  
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Table 2.1 List of primers used in this study. 
Gene Direction Sequence of primer pairs (5’ – 3’) * Product 
size (bp) 
Application 
CpACS1 Forward gtatatggatccATGGAAGAGAAAATCGACA 2058 Expression 
 Reverse ccacgatctagaTCAAATTTGTGATCTTAAAG   
CpACS2 Forward gaattaggatccATGGGGAACATTACTTCA 2052 Expression 
 Reverse gaacaatctagaTCATTCATTCTTAGGTTTTGAG   
CpACS3 Forward gaaataggatccATGAAGATTCTAAGATTAGC 2302 Expression 
 Reverse gaaccatctagaTCATAGCTTATTTCCTAATT   
CpACS1 Forward GCAGAAAGACAACAAGATGGC 102 qRT-PCR 
 Reverse TCCCTCAATTCTTTCTGGTGA   
CpACS2 Forward TATATGGGTGTTAGGGTGCCA 127 qRT-PCR 
 Reverse CCTGGACTGCTCCAATATGAA   
CpACS3 Forward TGGTGTCCAGGTTTCACTTTC 96 qRT-PCR 
 Reverse TTCAATTCACCAAGCCTCATC   
Cp18S Forward TTGTTCCTTACTCCTTCAGCAC 175 qRT-PCR 
 Reverse TCCTTCCTATGTCTGGACCTG   
Hs18S Forward GGC GCC CCC TCG ATG CTC TTA 189 qRT-PCR 
 Reverse CCC CCG GCC GTC CCT CTT A   
* Lowercase letters sequence represents the linker region 
 
 
volume. The reactions were incubated at 50 °C for 30 min to synthesize cDNA, heated at 
95 °C for 15 min to inactivate the reverse transcriptase and then followed by 40 thermal 
cycles of PCR amplification (95 °C for 20 sec, 58 °C for 30 sec and 72 °C for 30 sec) 
with a CFX96 Real-Time PCR detection system (Bio-Rad Labs, Hercules, CA). Primers 
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specific to CpACS genes and 18S rRNA were listed in Table 2.1. Each experimental 
condition included at least three biological replicates (RNA samples) and two technical 
replicates (qRT-PCR reactions). 
Threshold cycle (CT) values were used for computing the relative levels of 
expression, in which data were first normalized by computing the ΔCT values between 
CpACS mRNA (ΔCT[sample]) and Cp18S rRNA (ΔCT[Cp18S]) for all samples. PCR 
amplification efficiencies (ε) for individual genes were determined by equation  
 
! = 10!( !!"#$)       (1) 
 
in which slops were obtained by real-time qRT-PCR with a serial dilutions of a pooled 
total RNA sample, followed by linear regression of CT values against common 
logarithms of relative RNA concentrations (dilutions). Two types of relative expression 
levels were plotted. The first one was the percent levels of mRNA of a specified gene in 
various samples in relative to the one with the highest level of expression, which was 
derived from relative fold changes (f) determined by equation: 
 ! = !∆∆!!      (2) 
 
where ΔΔCT values were those between a specified sample and the highest one. Second, 
because the PCR amplification efficiencies for all three genes and Cp18S rRNA were 
nearly identical (i.e., ε  = 1.896 ± 0.017) (Figure 2.3B), we were able to also use the 
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ΔΔCT method to directly compare the relative levels of expressions between the three 
CpACS genes in all samples against the overall mean. 
2.2.4 Molecular cloning and heterogeneous expression 
CpACS1, CpACS2 and CpACS3 genes have been annotated by the C. parvum 
genome-sequencing project (GenBank accession numbers: XM_626649 for ACS1, 
XM_626248 for ACS2, and XM_625917 for ACS3). Their open reading frames (ORFs) 
were amplified from C. parvum genome DNA by PCR using high-fidelity Pfu DNA 
polymerase (Stratagene) and cloned into a pCR2.1-TOPO vector (Invitrogen). Cloned 
genes were sequenced to confirm their identities and then subcloned into pMAL-c2x 
expression vector (New England Biolabs) for expression as maltose-binding protein 
(MBP)-fusion proteins. Primers used for cloning were also listed in Table 2.1. Plasmids 
with correct sequences and orientation were transformed into a Rosetta 2 strain of 
Escherichia coli competent cells (Novagen) for protein expression. Briefly, a single 
colony of transformed bacteria was first inoculated into 50 ml LB media containing 
ampicillin (50 µg/ml), chloramphenicol (25 µg/ml), and glucose (2 mg/ml), and allowed 
to grow overnight at 30 °C in a shaking incubator. The overnight cultures were diluted 
1:20 with fresh medium and incubated for ~2 h at 37°C until their OD600 reached to ~0.5. 
Then, isopropyl-1-thio-β-D galactopyranoside (IPTG) was added to the cultures at a 
final concentration of 0.3 mM, and bacteria were allowed to grow for ~16 h under 16 °C 
to express proteins. The collection of bacterial pellets and purification of MBP-fusion 
proteins by an amylose resin-based affinity chromatography were followed 
manufacturer’s protocols (New England Biolabs, Ipswich, MA). 
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2.2.5 Production and affinity purification of anti-CpACS1, anti-CpACS2, and anti-
CpACS3 polyclonal antibodies 
Polyclonal antibodies against CpACS1, CpACS2 and CpACS3 were 
commercially produced by Alpha Diagnostic International (San Antonio, TX). 
Antibodies to CpACS1 was produced using a recombinant protein corresponding to the 
amino acids from position 99 to 254 in two specific pathogen-free (SPF) rabbits by a 
standard 63-day protocol, which included 5 injections at multiple sites at 14 day interval. 
Pre-immune bleed was collected prior to immunization, and two immune bleeds were 
collected at weeks 7 and 9, separately. For anti-CpACS3 antibody production, a 
recombinant protein corresponding to the amino acids from position 86 to 288 of 
CpACS3 was applied to generate anti-CpACS3 polyclonal antibodies in SPF rabbits 
with same protocol as CpACS1 antibodies producing. Antibodies to CpACS2 was 
generated in two SPF hen using synthesized peptide CTAAFVYGQLGREGTKLGSN 
corresponding to amino acids at positions from 271-290 by a standard 63-day 
immunization protocol, including isolation of chicken IgY from 6 egg yolks. 
Antibodies were subjected to an antigen-based affinity purification procedure 
using a previously described protocol with minor modification (153), Briefly, for 
CpACS1or CpACS3 antibodies, the recombinant CpACS1 or CpACS3 antigens were 
separated by SDS-PAGE and transferred onto nitrocellulose membranes. The blots were 
stained with Ponceau Red and the strips containing the recombinant proteins were cut 
out for subsequent antibody purification. For CpACS2 antibodies purification, synthetic 
peptide was directly blotted onto nitrocellulose membranes and air-dried. All membranes 
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were blocked with 5% BSA in TBST (Tris-buffered saline containing 0.02% Tween 20) 
for 1 h, and then incubated separately with anti-CpACS1 or anti-CpACS3 sera, or anti-
CpACS2 IgY overnight at 4 °C on an orbital shaker. The blots were washed three times 
with TBST (10 min each), and purified antibodies were eluted in 0.2 M Glycine (pH 2.2) 
by vigorous shaking on an orbital shaker for 2 minutes, and then quick neutralized with 
1 M Tris-HCl (pH 7.6) buffer. 
2.2.6 Immunofluorescence microscopy 
Free sporozoites were prepared by an in vitro excystation procedure, in which C. 
parvum oocysts were incubated in PBS containing 0.5% taurodeoxycholic acid (TDC) 
and 0.25% trypsin for 45 minutes at 37 °C. Freshly released sporozoites were collected 
and washed with culture medium containing 10% fetal bovine serum (FBS) to neutralize 
trypsin. Type I merozoites were collected from the supernatants of cultured HCT-8 cells 
infected with C. parvum for 12-18 h. Different intracellular stages of parasites were 
obtained by infecting HCT-8 cell monolayers cultured on glass coverslips for 3 to 24 h, 
followed by fixation of monolayers in 4% formaldehyde for 30 min at room temperature. 
After 3 washes in PBS, excessive formaldehyde was quenched with 50 mM NH4Cl for 
15 min. Fixed cells were permeabilized with 0.1% Triton X-100 and 0.02% SDS in PBS 
for 5 min, washed 3 times in PBS (5 min each). Cells were then blocked with 5% FBS in 
PBS for 30 min, followed by incubation with affinity-purified anti-CpACS antibodies 
(1:500 dilution in 5% FBS-PBS) for 30 min, three washes with 5% FBS-PBS, incubation 
with TRITC-conjugated goat anti-rabbit or rabbit anti-chicken IgG (1:400 dilution in 5% 
FBS-PBS) for 30 min, and three washes with 5% FBS-PBS. After an additional wash 
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with PBS, coverslips were mounted onto slides with a Prolong Gold Antifade reagent 
containing 4',6-diamidino-2-phenylindole (DAPI) for counter-staining of nuclei 
(Molecular Probes/Invitrogen, Grand Island, NY). Cells labeled with fluorescent 
molecules were examined with an Olympus BX51 research microscope equipped with 
appropriate filter sets. Images were captured with a Retiga SRV CCD Digital Camera 
(QImaging, Surry, BC). Fluorescence images were edited with Photoshop CS4. To better 
visualize the immunofluorescence labeling, images were subjected to adjustments of 
signal levels and color balance that were uniformly applied to the entire images without 
local manipulations. 
2.2.7 Biochemical assays 
All chemicals used in the present study were purchased from Sigma-Aldrich (St. 
Louis, MO) or as specified. Triacsin C was purchased from Fermentek LTD (Jerusalem, 
Israel). The activity of CpACS enzymes were determined by monitoring the reduction of 
CoA concentrations by a 5,5’-Dithio-bis-(2-nitrobenzoate) (DTNB, Ellman’s reagent) 
colorimetric assay. In this assay, free CoA-SH reacted with DTNB to form 5-
thionitrobenzoic acids that could be measured at 412 nm (154,155). A typical assay was 
performed in 200 µL reaction buffer (0.1 M Tris-HCl pH 8.0) containing 10 mM KCl, 
10 mM MgCl2, 50 µM CoA-SH, 200 µM ATP and 100 µM fatty acid. A panel of fatty 
acids with varied chain lengths (C2:0 to C30:0) was individually assays to determine the 
substrate preferences for CpACS enzymes. The reactions were started with the addition 
of 1 µg of freshly purified MBP-CpACS fusion proteins. After incubation for 10 min at 
32 °C, reactions were stopped by heating sample at 80 °C for 5 min. After samples 
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cooled down to room temperature, 4 µL of 5 mM DTNB was added into each reaction, 
followed by 5 min of color development. OD412 was measured with a Multiskan 
Spectrum spectrophotometer (Thermo Scientific, West Palm Beach, FL). The CoA-SH 
concentration was calculated according to the standard curve using serially diluted CoA-
SH solutions. 
Enzyme kinetics towards substrates was similarly assayed with varied substrate 
concentrations (i.e., palmitic acid at 0 – 600 µM and ATP at 0 – 3000 µM, respectively). 
Guanosine triphosphate (GTP), cytidine triphosphate (CTP) and uridine triphosphate 
(UTP) were used to replace ATP in the assay to test whether they could serve as 
alternative energy sources for CpACS enzymes. The inhibitory effects of triacsin C on 
CpACS enzymes were analyzed under similar reaction conditions, except that 1 to 32 
µM of triacsin C was added to reactions. In all experiments, MBP-tag alone was used as 
control. All assays were carried out in at least duplicate, and at least two independent 
assays were performed for each experiment. 
2.2.8 Drug efficacy against parasite growth in vitro 
A quantitative real-time RT-PCR (qRT-PCR) assay was used to evaluate the drug 
efficacy against C. parvum growth in vitro (150,152). Human HCT-8 cells (ATCC # 
CCL-225) was seeded into 24-well cell culture plates and allowed to grow overnight at 
37 °C under an atmosphere of 5% CO2 in RPMI 1640 medium (Sigma) containing 10% 
fetal bovine serum (FBS) or until they reached ~80% confluence. Purified C. parvum 
oocysts (less than 3 months old) were added into the cell culture at a parasite:host cell 
ratio of 1:2 (i.e., 1 x 105 oocysts/well), and allowed to infect host cells for 3 h. Parasites 
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that failed to invade host cells were removed by a medium exchange and tiracsin C were 
added in the medium (0.2% DMSO). Parasite-infected cells were allowed to grow for 
additional 41 h. To test the effect of triacsin C on parasite invasion, excystated 
sporozoites were prepared as described in Section 2.2.1. Sporozoites were incubated 
with triacsin C at specified concentrations for 30 min at 37 °C, washed with PBS to 
remove drug, and allowed to invade HCT-8 cells for 3 h. Prior to RNA isolation, 
monolayers were gently washed 3 times with nuclease-free PBS and lysed in 350 µl of 
lysis buffer. 
Total RNA was isolated from drug treated and untreated cells infected with C. 
parvum using an RNeasy Minikit (Qiagen Inc., Valencia, CA). These RNA samples 
were also treated with RNase-free DNase (Qiagen) to remove DNA according to the 
manufacturer’s protocol. The quality and purity of RNA were determined using a 
NanoDrop ND-1000 spectrophotometer at 260/280 nm (Nano-Drop Technologies, 
Wilmington, DE). A Qiagen one-step RT-PCR QuantiTect SYBR green RT-PCR kit was 
employed to evaluate the parasite growth. Parasite growth in HCT-8 cells was assayed 
by detecting the relative levels of parasite 18S rRNA normalized using human 18S 
rRNA as control as described previously (150,152). Primers used in the assay were listed 
in Table 2.1. Cytotoxicity of triacsin C on host cells was evaluated by the relative levels 
of 18S rRNA in uninfected HCT-8 cells and by a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay kit (Sigma) as previously described (23). 
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2.2.9 Drug efficacy in vivo using a mouse model of acute cryptosporidiosis 
The anticryptosporidial activity of triacsin C was assessed in the IL-12 knockout 
mouse model. The experiments were performed in collaboration with Dr. Jan R. Mead at 
the Emory University/Atlanta VA Medical Center. Like other mouse models of 
cryptosporidiosis, this model does not demonstrate frank signs of diarrhea. However, it 
represents an acute model in that mice have rapidly intensifying parasite loads but then 
recover by day 14 (101). In this study, C. parvum oocysts (IOWA strain) were collected, 
purified through discontinuous sucrose and cesium chloride gradients and stored as 
previously described (156). Oocyst inoculation was prepared by washing purified 
oocysts (stored <6 months) with PBS (pH 7.2) to remove potassium dichromate. Mice (6 
- 8 weeks old) were inoculated with 1,000 oocysts and treated by gavage with triacsin C, 
vehicle control (10% PEG or 1% DMSO), or paromomycin (2 g/kg/d, positive control). 
Treatment was given once daily for 7 days and mice sacrificed on day 8 (peak infection). 
At least 10 mice were used for each experimental condition. Parasite burden was 
assessed by flow cytometry as previously described (157). Briefly, fecal samples were 
collected from individual mice on 5 and 7 days post-inoculation (dpi) and processed 
through microscale sucrose gradients in 2.0 ml microcentrifuge tubes. The partially 
purified stool concentrates containing oocysts were incubated for 30 min at 37 °C with 
5 µl of an oocyst wall-specific monoclonal antibody conjugated with fluorescein 
isothiocyanate (OW50-FITC) and then analyzed by flow cytometry. Absolute counts 
were calculated from the data files as oocysts per 100 µl of sample suspension (55).  
 
  42 
2.2.10 Data analysis and statistics 
All biochemical and in vitro drug assays were performed at least in duplicate, 
and at least two independent assays were performed for each experiment. However, only 
data derived from single experiments are shown in the figures. In vivo drug testing was 
performed in two separate experiments. Data were typically analyzed using Microsoft 
Excel (Office 2011) and GraphPad Prism v5.0f (http://www.graphpad.com). In qRT-
PCR analysis for gene expressions and in vitro drug testing, linear and appropriate 
nonlinear regressions were performed for specified qRT-PCR datasets. Statistical 
significances were assessed by two-tailed Student's t-test, Mann-Whitney nonparametric 
test (not assuming Gaussian distributions), and by two-way ANOVA. 
2.2.11 Ethics statement 
This study was performed in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health 
(NIH) under the Animal Welfare Assurance Numbers A4168-01 (Atlanta VA Medical 
Center) and A3893-01 (Texas A&M University). All animal experiments were 
performed in accordance with procedures approved by the Institutional Animal Care and 
Use Committees of Atlanta VA Medical Center (protocol # V001-06) and Texas A&M 
University (protocol # 2009-21). 
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2.3 Results 
2.3.1 CpACS enzymes belong to the long-chain ACS subfamily 
ACS enzymes can be divided into four major subfamilies based on the chain 
length of their preferred acyl groups: short-chain (C2 - C4) (SC)-ACS, medium-chain 
(C4 - C12) (MC)-ACS, long-chain (C12 - C20) (LC)-ACS, and very long-chain (C18-
C26) (VLC)-ACS (134,158). The number of LC-ACSs varies among different organisms 
(e.g., at least 9 in Arabidopsis thaliana, 11 in Plasmodium falciparum and 5 in humans) 
(148,158,159). Each of the three sequenced Cryptosporidium genomes (i.e., C. parvum, 
C. homins and C. muris) contains three LC-ACS genes. Our sequence analysis indicated 
that LC-ACSs are closely related to VLC-ACSs. Phylogenetic trees inferred from 
chromalveolate orthologs by ML and BI methods divided the LC- and VLC-ACS 
proteins into 4 major clusters (Figure 2.1): clusters I and II with top hits to eukaryotic-
type LC-ACS domains in the NCBI conserved domain database (e.g., LC-ACS-euk 
[cd05927]); cluster III with Firefly Luc-like (cd05911) and uncharacterized FACL-like-2 
(cd05917) domains; and cluster IV with VLC-ACS (cd05907) and bubblegum VLC-
ACS (cd05933). Sequences from stramenopiles and ciliates were present in all 4 
clusters, while those from a dinoflagellate (Perkinsus) and apicomplexans were mainly 
present in clusters I and II, except of Toxoplasma and Neospora. Toxoplasma and 
Neospora both had two ACS sequences in cluster IV.  
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Figure 2.1 Phylogenetic tree inferred from ACS proteins among chromalveolates using 
Bayesian inference (BI) and maximum likelihood (ML) methods. Numbers at the nodes 
indicate posterior probability and bootstrapping proportion supporting values obtained in 
BI and ML analyses. Numbers of sequences contained in specified clusters are indicated 
in parentheses after the taxonomic names. 
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These observations suggest that: 1) there was an ancient split between LC- and 
VLC-ACS genes that predated the split between alveolates and stramenopiles; 2) VLC-
ACS genes were lost in most apicomplexans and in at least one dinoflagellate 
(Perkinsus), but were retained in some coccidia (e.g., Toxoplasma and Neospora); and 3) 
gene expansions occurred within each group, particularly among the LC-ACS genes in 
clusters I and II. 
All Cryptosporidium ACS proteins were predicated to be LC-ACS enzymes in 
cluster I, which was confirmed by biochemical analysis as described below. The three 
CpACS proteins contained two conserved domains: the AMP/ATP-binding motif 
(TSGTTGxPK) and the fatty acyl-CoA synthetase signature motif 
(TGDIxxxxxxGxxxIxDRxK) (Figure 2.2A). The AMP/ATP-binding sites are highly 
conserved not only in the ACS family, but also in many other ATP-dependent AMP-
binding enzymes for adenylate formation (144,160). Signal peptides (SP) were absent in 
both the CpACS1 and CpACS2 proteins. However, SignalP analysis indicated the 
presence of an N-terminal signal peptide for secretion (S-score: 0.97) with a predicted 
cleavage site between amino acid positions 22 and 23 of CpACS3 (Figure 2.2B).  
2.3.2 CpACS genes were differentially expressed and their proteins were localized to 
different subcellular structures 
Having established that the CpACS genes likely encode long-chain ACS 
enzymes, we wanted to confirm the expression and localization of these enzymes.  This 
information could provide additional insight into the biological function of these  
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Figure 2.2 Structures and domains for CpACS1, CpACS2 and CpACS3 proteins. A) 
Domain organization and sequence logos of amino acids conserved among 
chromaveolates; B) Prediction of N-terminal signal peptide (sp) for secretion in CpACS3 
by SignalP algorithm, in which S-score predicts signal peptide, while C-score and Y-
score predict cleavage site. 
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Figure 2.3 Differential expression of the 3 CpACS genes in C. parvum at different life 
cycle stages as determined by qRT-PCR. A) Standard curves showing linear relationship 
between detection threshold cycles (CT values) and the levels of CpACS transcripts 
using serially diluted, pooled total RNA isolated from infected HCT-8 cells. Cp18S 
rRNA was used as control for normalization; B) PCR amplification efficiencies of 
Cp18S rRNA and CpACS transcripts derived from standard curves; C) Normalized 
levels of three CpACS transcripts in different life cycle stages in relative to the highest 
level for each gene (i.e., comparison between different developmental stages, but not 
between different genes); D) Normalized levels of three CpACS transcripts in relative to 
the overall mean of all three genes in all developmental stages. 
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enzymes. We examined the levels of CpACS transcripts and protein localizations in 
various parasite developmental stages by qRT-PCR and immunofluorescence 
microscopy, respectively. Because the PCR amplification efficiencies for all three genes 
and Cp18S rRNA were nearly identical (i.e., ε  = 1.896 ± 0.017) (Figure 2.3A and 2.3B), 
we were able to use the ΔΔCT method to directly compare the relative levels of 
expressions of between three CpACS genes in all samples against the overall mean 
(Figure 2.3D). We also compared the mRNA levels of a specified gene in various 
samples (Figure 2.3C). Real-time qRT-PCR based analysis revealed that CpACS genes 
were differentially expressed at different parasite developmental stages (Figures 2.3C 
and 2.3D). More specifically, the CpACS1 and CpACS2 genes were expressed at much 
higher levels in the early and later intracellular developmental stages, respectively. On 
the other hand, the CpACS3 gene had much higher levels of expression in oocysts and 
sporozoites (Figure 2.3C). These observations suggest that the three CpACS enzymes 
might play different roles during the parasite development. 
This notion was also supported by immunofluorescence staining using affinity-
purified polyclonal antibodies against the three CpACS proteins (Figures 2.4, 2.5 and 
2.6). CpACS1 was highly concentrated in the anterior region of free sporozoites and 
merozoites (Figure 2.4), which corresponding to the region containing apicomplexan-
specific secretory organelles micronemes and rhoptries. CpACS1 protein was briefly 
retained in the anterior region after sporozoites and merozoites entered host cells (i.e., 
single-nuclear early stage of merogony), fully dissolved in the mid-stage of  
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Figure 2.4 Immunofluorescence labeling of CpACS1 protein in C. parvum sporozoites 
(Spz), merozoites (Mrz) and intracellular developmental stages. Abbreviations: a, 
anterior region of sporozoites or merozoites; p, posterior region of sporozoites or 
merozoites; em, early stage meronts; m, meronts; r, merozoites; v, parasitophorous 
vacuole membrane. 
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Figure 2.5 Immunofluorescence labeling of CpACS2 protein in C. parvum sporozoites 
(Spz), merozoites (Mrz) and intracellular developmental stages. See Figure 2.4 legend 
for abbreviations. 
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Figure 2.6 Immunofluorescence labeling of CpACS3 protein in C. parvum sporozoites 
(Spz), merozoites (Mrz) and intracellular developmental stages. See Figure 2.4 legend 
for abbreviations. 
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multi-nuclear meronts with no or weak fluorescence signal, and then reappeared in the 
anterior region of intracellular merozoites in the late stage of merogony (Figure 2.4). 
Additionally, weak signals were also observed in parasitophorous vacuole membrane 
(PVM). Based on these observations, we speculate that CpACS1 is probably stored in 
rhoptries and/or micronemes, and mainly participates in the activation of fatty acids that 
may be required in the early stage of intracellular development. 
On the other hand, CpACS2 protein was highly concentrated in the cytoplasmic 
membranes in virtually all stages of C. parvum, including free sporozoites and 
merozoites, and intracellular parasites at various developmental stages (Figure 2.5). 
CpACS2 protein was also present in the PVM. However, it was highly concentrated in 
certain region with focal points slightly different from those of intracellular merozoites 
towards host cells, similar to a previously reported ATP-binding cassette (ABC) 
transporter (161), suggesting that this enzyme might be more concentrated at the 
parasite-host cell interface than in PVM. These observations suggest that CpACS2 may 
play a general house-keeping role in the parasite, and may be involved in the scavenging 
of fatty acids from host cells. 
CpACS3 distributed in a similar pattern as CpACS2 in the parasite cells, i.e., 
highly concentrated on the cytoplasmic membranes in sporozoites, merozoites and 
intracellular parasites (Figure 2.6). However, unlike CpACS2, there was no or little 
CpACS3 on the PVM during the intracellular developmental stages, suggesting that 
CpACS3 may mainly function in the parasite cells, but less likely be involved in the 
uptake of fatty acids from host cells across the PVM or feeder organelle. 
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Figure 2.7 Activation of long chain fatty acids by C. parvum ACSs. Substrate 
preferences of recombinant CpACS1 and CpACS2 proteins towards variable carbon 
chain lengths of saturated fatty acids as determined by DTNB assay. Activities are 
expressed in relative to C16 palmitic acid. 
 
 
 
 
2.3.3 CpACS1 and CpACS2 activate long-chain fatty acids 
To test whether or not the CpACSs represent bona-fide fatty acid activating 
enzymes, we attempted to clone and express these proteins as MBP-fusion proteins in 
bacteria and examined their activity against saturated fatty acids. All three CpACS genes 
could be amplified by PCR, cloned into the pCR2.1-TOPO cloning vector, and 
subcloned into the expression vector pMAL-c2x. However, only CpACS1 and CpACS2 
have been successfully expressed as recombinant proteins (Figure 2.7, inset). Numerous 
  54 
attempts to express recombinant CpACS3 were unsuccessful, including the use of 
different expression conditions and vectors. Therefore, biochemical analyses reported 
here were focused on the recombinant CpACS1 and CpACS2 to gain knowledge of 
biochemical features representing CpACS enzymes in general. 
Classic ACS assays use radioactive substrates coupled with isopropanol and/or 
heptane extractions [e.g. (162,163)]. Here we adapted a colorimetric assay using 5,5’-
Dithio-bis-(2nitrobenzoate) (DTNB, Ellman’s reagent) to assess enzyme kinetics and 
inhibitor effects by measuring the reduction of thiol-groups of free CoA-SH in the 
reactions (164). This method is more user-friendly, safer, and suitable for adaptation to 
high-throughput screening. Both CpACS1 and CpACS2 displayed a clear preference 
towards 12- to 18-carbon fatty acids and lower activities toward C10:0 and C20:0 
(Figure 2.7). These two enzymes had no or little activity on saturated fatty acids that are 
less than 10 carbons or greater than 20 carbons in length, except for CpACS2 which 
displayed low activity towards some VLC fatty acids. The data agree with the functional 
prediction based on phylogenetic reconstructions. 
CpACS1 and CpACS2 followed Michaelis-Menten kinetics towards C16:0 
(palmitic acid) and ATP with Km values in the lower µM and nM levels, respectively 
(Table 2.2 and Figures 2.8A and 2.8B). The two enzymes were Mg2+-dependent, and 
their activities peaked at ~1 mM Mg2+ concentrations (Figure 2.8C). Both enzymes 
could only utilize ATP as their energy source, as no activities were observed when GTP, 
CTP and UTP were used in the reactions (Figure 2.8D), which was similar to the P. 
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falciparum ACS1 and the ACL-domain in the C. parvum polyketide synthase (CpPKS1) 
(162,163). 
 
 
Table 2.2 CpACS1 and CpACS2 enzyme kinetics towards substrates and inhibitor 
Substrate or 
inhibitor 
Parameter CpACS1 CpACS2 
Palmitic acid Km (µM) 38.30 7.21 
Palmitic acid Vmax (mmol/mg/min) 0.60 0.78 
ATP Km (µM) 0.26 0.17 
ATP Vmax (mmol/mg/min) 0.81 1.62 
Triacsin C IC50 (µM) 3.70 2.32 
Triacsin C Ki (µM) 0.60 0.11 
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Figure 2.8 Biochemical features of CpACS1 and CpACS2 as determined using 
recombinant proteins. A) Enzyme kinetics towards palmitic acid; B) Enzyme kinetics 
using ATP; C) Dose-dependent activity using Mg2+; D) Enzyme activities using different 
nucleoside triphosphates (NTPs). 
 
 
 
2.3.4 Triacsin C inhibited CpACS enzyme activities and was highly effective against 
C. parvum growth both in vitro and in vivo 
To assess whether or not CpACS enzymes are amenable to inhibition by small 
molecules, we examined enzyme activities in the presence of triacsin C (CAS # 76896-
80-5; synonym: 2,4,7-undecatrienal nitrosohydrazone) that is a fungal metabolite 
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originally isolated from Streptomyces aureofaciens and identified as a vasodilator 
(165,166). It resembles a polyunsaturated fatty acid (see Figure 2.9B inset) and can 
differentially inhibit various LC-ACSs  (167-172). For example, in humans, it can inhibit 
LC-ACSs, but has little effect on SC-ACSs or mitochondrial MC-ACSs (170). In rats, 
this compound was effective on ACSL1, ACSL3 and ACSL4 at low µM levels, but was 
not effective against ACSL5 and ACSL6 (171,172). In the present study, we observed 
that triacsin C could inhibit CpACS1 and CpACS2 enzyme activities with IC50 values at 
3.70 µM and 2.32 µM (Table 2.2 and Figure 2.9A), corresponding to Ki values at 595 
nM and 106 nM, respectively, as calculated using a competitive inhibition model (173). 
Given that triacsin C displayed significant inhibition of the CpACS enzymes in 
vitro, we wished to determine if this compound was effective at inhibiting parasite 
growth. Triacsin C displayed strong efficacy against the growth of C. parvum cultured 
with HCT-8 cells at nM levels (i.e., IC50 = 136 nM) (Figure 2.9B), although a short 30-
min treatment on sporozoites did not affect parasite invasion (Figure 2.9C). There were 
no significant effects of triacsin C on the HCT-8 host cells based on the Hs18S rRNA 
levels (Figure 2.9D), and MTT assay suggested a moderate decrease in host cell 
metabolism when this inhibitor was used at 1 µM or higher for 2 days (Figure 2.9E). 
The promising results of triacsin C against both CpACS enzyme activity and 
parasite growth in vitro motivated us to examine how triacsin C would affect the 
pathogenesis of disease in a mouse model of acute cryptosporidiosis. In vivo drug testing 
using an IL-12 knockout mouse model of acute cryptosporidial infection revealed that  
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Figure 2.9 Inhibition of enzyme activity and parasite growth in vitro. A) Inhibition of 
CpACS1 and CpACS2 enzyme activities by triacsin C; B) Efficacy of triacsin C on the 
growth of C. parvum cultured in vitro with HCT-8 cells using a qRT-PCR assay at 44h 
post-infection (hpi); C) Relative level of invasion by sporozoites receiving 30-min 
treatment of triacsin C determined at 3 h post infection (hpi); D) Effect of triacsin C 
treatment on the Hs18S rRNA levels in the uninfected HCT-8 cells; E) Effect of triacsin 
C on uninfected HCT-8 cell metabolism by an MTT assay. Asterisks indicate groups 
with statistically significant differences when compared untreated controls (p < 0.05). 
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triacsin C could effectively inhibit the parasite growth at therapeutic levels. At a dose of 
8 mg/kg/d, triacsin C reduced C. parvum oocyst production in feces by 62.50% and 
54.73% on 5 and 7 dpi, respectively; while at 15 mg/kg/d the reductions reached 78.91% 
and 88.11% on 5 and 7 dpi, respectively (Figure 2.10A). Both Student’s t-test and 
nonparametric test indicated the reductions were significant in all treated groups except 
for the 8 mg/kg/d group. Two-way ANOVA also showed significant differences in 
percent inhibitions between the two doses of triacsin C treatments (p = 0.020), but not 
between 5 and 7 dpi (p = 0.316) (Figure 2.10A). Additionally, gross histology of IL-12 
knockout mice administered 8 or 15 mg/kg/d doses of triacsin C revealed no observable 
pathology in the major organs (data not shown). Moreover, triacsin C treatments at the 
two doses resulted in a general improvement in weight gain in mice infected with C. 
parvum, although the improvement was not statistically significant by Student’s t-test or 
Mann-Whitney test (Figure 2.10B). 
The observed therapeutic index of triacsin C against cryptosporidial infection in 
mice was more than 10 times better than nitazoxanide (the only FDA-approved drug to 
treat human cryptosporidiosis) and paromomycin (a “golden standard” anti-
cryptosporidial control drug), as these two classic anti-cryptosporidial drugs could only 
effectively inhibit cryptosporidial infections in various animal models at doses between 
0.2 – 2 g/kg/d (Figure 2.10A) [also see review (174)]. 
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Figure 2.10 Efficacy of triacsin C on cryptosporidial infection in IL-12 knockout mice.  
A) Relative production of C. parvum oocysts on 5 and 7 days post-infection (dpi). 
Numbers in or above the bars indicate average oocyst counts (per 100µL) in each 
experimental group. Asterisks indicate statistically significant difference by a 
nonparametric Mann-Whitney test when compared with controls (* = p < 0.05; ** = p < 
0.01; *** = p < 0.001). Student’s t-test produced the same result, albeit with smaller p 
values (all < 0.05); B) Relative weight gains in mice on day 7 pi. No significant 
difference in mice weight gain was showed between different treatment within and 
between two experiments. 
 
 
 
A 
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Nitazoxanide and paromomycin are known for their low toxicity to humans and animals 
(e.g., oral LD50 values for acute toxicity in mice at 1.35 and 23.5 g/kg/d, based on the 
Registry of Toxic Effects of Chemical Substances database). Although toxicity of 
triacsin C in mice remains to be determined, this compound was not toxic to mice at the 
low mg/kg/d levels used here and in other studies (175,176). 
 
2.4 Discussion 
We identified three long chain fatty acyl-CoA synthetase (LC-ACS) genes in the 
C. parvum genome that were differentially expressed during the complex parasite life 
cycle. Their protein sequences were 98% (ACS3) to 100% (ACS1 and ACS2) identical 
to the orthologs in C. hominis, or 73% to 76% identical to those from C. muris. CpACS1 
and CpACS2 were successfully expressed as MBP-fusion proteins. Even though 
different strategies have been explored to express CpACS3 in E. coli, we were still 
unable to get induced CpACS3 protein. It might due to potential cytotoxicity of this 
protein to E. coli, which likes P. falciparum ACS1 (163). However, our biochemical 
analysis on CpACS1 and CpACS2 provide sufficient insights on the biochemical 
features of this family of enzymes in C. parvum. The DTNB-based colorimetric assay 
not only permits the measurements of enzyme activity and the effect of inhibitors, it can 
also be easily adapted for high-throughput screening of drugs against ACS.  
Despite that LC-ACS enzymes are essential in fatty acid metabolism and present 
in multiple forms in various apicomplexans, little is known on their biochemical 
features. In fact, only one earlier study had assayed the ACS activity in crude extract of 
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P. knowlesi-infected simian erythrocytes (177), and a relatively simple biochemical 
analysis was performed specifically on a single P. falciparum ACS (i.e., PfACS1) 
protein (163). In C. parvum, one of the three ACS genes (corresponding to CpACS3) was 
previously identified by screening an expression library with a monoclonal antibody 
(178), but no biochemical analysis was performed. The lack of functional study on 
apicomplexan ACSs might be in part due to the technical difficulties in expressing 
and/or obtaining enzymatically active recombinant proteins as noted in expressing 
CpACS3 (this study) and PfACS1 (163). Therefore, our observation that recombinant 
CpACS1 and CpACS2 proteins retain activity for only a very short time and need to be 
assayed immediately after purification is a critical one, and should be kept in mind when 
studying other recombinant apicomplexan ACS enzymes. On the other hand, addition of 
10 mM of ATP in protein stocking buffer can improve CpACS stability as shown in 
stocking of E. coli FadR (ACS) (179). Although the ATP in stocking buffer will affect 
the analysis of biochemical features, high-throughput screening of drugs against 
CpACSs will greatly benefit from the stability improvement of CpACS proteins. 
The most significant observation is the excellent efficacy of ACS inhibitor 
triacsin C against cryptosporidial infection in mice. Because of the lack of completely 
effective drugs for cryptosporidiosis in humans and animals, particularly in AIDS 
patients, great efforts have been devoted to the drug discovery against this parasite. Drug 
screenings have, in fact, identified many compounds highly effective against the growth 
of C. parvum in vitro, but most (if not all), including nitazoxanide and paromomycin, 
failed to achieve comparable efficacies when tested in animals (174,180). The present 
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study shows that triacsin C effectively inhibited specific drug targets CpACS1 and 
CpACS2, displayed excellent therapeutic indexes against the growth of C. parvum in 
vitro (i.e., IC50 = 136 nM), and could reduce C. parvum oocyst production in mice by 
~50% to 88% at pharmaceutically achievable levels (i.e., 8-15 mg/kg/d). 
It is known that triacsin C may also inhibit LC-ACS enzymes in humans and 
animals, thus affecting certain aspects of lipid metabolism. For example, treatment of 
human hepatocytes with triacsin C reduced the formation of lipid droplets (181), while 
in human fibroblast cells, it could block de novo synthesis of glycerolipids and 
cholesterol esters (182). However, triacsin C did not affect the recycling of fatty acids 
into phospholipid, which not only suggests the presence of functionally separate pools of 
acyl-CoA, but also explains why no apparent toxicity occurred in the animals used here 
and previous studies (182). Although triacsin C has not been tested or therapeutically 
used in humans, several studies in animals have shown the benefits of triacsin C 
treatment. For example, in vitro and in vivo experiments in chickens have shown that 
triacsin C could rescue palmitic acid-induced cytotoxicity of follicle granulosa cells in 
fuel-overloaded broiler hens (183). In mice, triacsin C displayed activities to control 
cancer growth and enhance the efficacy of etoposide at a non-toxic dose (4 mg/kg/d) 
(175), and anti-atherosclerotic activity when administrated at a dose of 10 mg/kg/d 
(184). These observations suggested that, although pharmacokinetics and toxicity tests 
are needed to further evaluate the safety, triacsin C is generally safe in animals when 
administrated at low mg/kg/d doses, and that its potential as a new anti-cryptosporidial 
drug should be explored. In fact, triacsin C is also an effective inhibitor against the acyl-
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CoA-[ACP]-ligase domains in the unique, multi-functional type I fatty acid synthase 
(FAS1) and polyketide synthase (PKS1) in C. parvum (162). Therefore, triacsin C has 
the potential to hit multiple targets and to block both the fatty acid activation by discrete 
ACSs, as well as elongation of fatty acids by FAS1 and PKS1.  
Finally, whether triacsin C could be truly developed into a new anti-
cryptosporidial drug may require a serial pharmacokinetic, preclinical and clinical tests, 
the present study strongly supports that the discrete ACSs (and ACL domains in FAS1 
and PKS1) can serve as novel drug targets. New triacsin C analogs can be synthesized 
and new classes of anti-ACS compounds may be identified by drug screening for 
developing more selective and safe anti-cryptosporidial drugs.  
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3 SUMMARY AND CONCLUSION 
 
C. parvum is a unicellular zoonotic pathogen that can cause severe watery 
diarrhea in both humans and animals (185). Individuals with immune system 
dysfunction, such as recipients of chemotherapy and AIDS patients are at high risk 
because C. parvum can cause a severe and sometimes fatal diarrhea to them. More 
significantly, Cryptosporidium is emerging as one of the four top diarrheal pathogens in 
children <2 years old in developing countries (69). Although the introduction of HAART 
has tremendously decreased the cryptosporidiosis on AIDS patients in developed 
countries, HAARP is not widely available in developing countries. Moreover, 
cryptosporidiosis is not always associated with AIDS in children, and HAARP may not 
eligible for non-HIV infected children. In the United States however, FDA approved 
treatments remain unavailable to treat this opportunistic infection in patients with AIDS, 
whereas only nitazoxanide is approved for use in immunocompetent individuals. 
Therefore, there is an urgent need for new drugs, particularly those that can be safely 
used in children and immunocompromised persons. 
In the present study, we explored the parasite fatty acyl-coenzyme A synthetase 
(ACS) as a novel drug target. ACS catalyzes the thioesterification between free fatty 
acids and CoA to form fatty acyl-CoAs. Fatty acyl-CoA is the active form of fatty acids, 
which will enter various metabolic pathways, such as β-oxidation, membrane lipid 
synthesis. Because fatty acids have to be activated by ACS to form acyl-CoA thioesters 
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before they involve in different biological pathways, ACS is essential in virtually all 
organisms.  
 The C. parvum genome encodes three potential ACSs, and they all cotain 
AMP/ATP binding domain and fatty acyl-CoA synthetase signature domain that are 
functional essential to ACS family enzyme. Phylogenetic tree inferred from ACS 
proteins among chromaleolates showed that all CpACSs proteins were predicted to be 
long chain ACS. Our biochemical result also confirmed that CpACS1 and CpACS2 both 
displayed a clear preference towards long chain fatty acids (C12- to C18- carbon). In 
vitro HCT-8 cells infection assays showed that three CpACSs were expressed in all 
parasite life cycle stages, but differed in their transcription profiles. For example, 
CpACS1 was highly expressed during first generation merogonic development, CpACS2 
during second generation of merogony, and CpACS3 in oocyst and sporozoites stages. 
The different transcription patterns of CpACSs suggest that they might play different 
roles during the parasite development.  
Indirect immunoflouresence labeling showed that CpACS1 protein was mainly 
located in the anterior region of the free sporozoites and merozoites, and disappeared in 
the middle multinuclear meront stage. CpACS2 protein was highly concentrated in the 
cytoplasmic membranes in virtually all stages of C. parvum, and also in PVM. CpACS3 
showed similar localization pattern as CpACS2 in parasites, but not present in PVM. The 
different subcellular localizations of CpACSs further support the notion that they play 
different role during parasite development.  
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We observed that Triacsin C, one typical ACS inhibitor, could inhibit CpACS1 
and CpACS2 enzyme activities at low µM levels. In vitro assay on C. parvum infected 
HCT-8 cells, triacsin C displayed strong efficacy against the growth of C. parvum at low 
nM levels. Furthermore, in vivo assay performed on IL-12 knockout mice model of 
acute cryptosporidiosis demonstrated that the effective dose of triacsin C against C. 
parvum infection was more than 10 times better than paromomycin and nitazoxanide.  
In summary, we have provided compelling evidence that fatty acid metabolism in 
C. parvum is essential and amenable to inhibition. The three CpACSs showed different 
transcription patterns and subcellular localizations. Both CpACS1 and CpACS2 prefer to 
use long chain fatty acids, and their enzyme activities can be inhibited by triacsin C, 
which is a long chain fatty acids analog. Triacsin C was highly effective against C. 
parvum growth in vitro (IC50 = 136 nM). Most importantly, triacsin C effectively 
reduced parasite oocyst production up to 88.1% with no apparent toxicity when 
administered to Cryptosporidium-infected interleukin 12 knockout mice at 8–15 mg/kg/d 
for 1 week. The findings of this study not only validated CpACSs as pharmacological 
targets, but also indicated that triacsin C and analogues can be explored as potential new 
therapeutics against the virtually untreatable cryptosporidial infection in 
immunocompromised patients. 
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